Table 66Summary evidence profile for olanzapine versus placebo (efficacy and self-harm/suicidality data)

SymptomAggressionAngerDepressionMental distressSelf-harmSuicidalityBorderline personality disorder symptomatology
Clinician-rated effect sizeSMD = 0.04 (−0.12, 0.2)SMD = −0.18 (−0.4, 0.04)SMD (random effects)= −0.21 (−0.53, 0.1)RD = 0.00 (−0.03, 0.03) 5% versus 3%SMD = −0.26 (−0.43, −0.1)*SMD = −0.15 (−0.31, 0.01)*
 Quality of evidenceModerateModerateVery lowHighModerateModerate
 Number of studies/participants(K = 2; n = 585)(K = 1; n = 314)(K = 2; n = 557)(K = 2; n = 608)(K = 2; n = 586)(K = 2; n = 596)
Forest plotPharm 03.01Pharm 04.02Pharm 11.01Pharm 12.01Pharm 12.02Pharm 14.01
Self-rated effect sizeSMD = 0.45 (−0.23, 1.13)
 Quality of evidenceVery low
 Number of studies/participants(K = 1; n = 34)
Forest plotPharm 07.05
*

Based on skewed data.

From: 6, PHARMACOLOGICAL AND OTHER PHYSICAL TREATMENTS IN THE MANAGEMENT OF BORDERLINE PERSONALITY DISORDER

Cover of Borderline Personality Disorder
Borderline Personality Disorder: Treatment and Management.
NICE Clinical Guidelines, No. 78.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2009.
Copyright © 2009, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.